Menke-Hennekam syndrome

From WikiMD's Medical Encyclopedia

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's medical weight loss NYC, sleep center NYC
Philadelphia medical weight loss and Philadelphia sleep clinics

Menke-Hennekam syndrome
Synonyms
Pronounce
Specialty Medical genetics
Symptoms Developmental delay, intellectual disability, facial dysmorphism, skeletal abnormalities
Complications N/A
Onset Infancy
Duration Lifelong
Types N/A
Causes Mutations in the CREBBP gene
Risks
Diagnosis Genetic testing, clinical evaluation
Differential diagnosis Rubinstein-Taybi syndrome, Cornelia de Lange syndrome
Prevention N/A
Treatment Supportive care, therapies for developmental delay
Medication
Prognosis Variable, depending on severity
Frequency Rare
Deaths


Menke-Hennekam Syndrome is a rare genetic disorder characterized by a range of physical and developmental anomalies. It is caused by mutations in the CDH1 gene, which plays a crucial role in cell adhesion and signaling pathways essential for the proper development of various tissues and organs. The syndrome was first described by Menke and Hennekam in the early 21st century, following the observation of patients with a unique set of clinical features not fitting into any known syndromic categories at the time.

Symptoms and Characteristics[edit]

Menke-Hennekam Syndrome is marked by a spectrum of clinical manifestations, including but not limited to:

  • Intellectual Disability: Most individuals with this syndrome exhibit some degree of intellectual disability or developmental delays.
  • Facial Dysmorphisms: Distinctive facial features may include a wide nasal bridge, deep-set eyes, and a small chin.
  • Gastrointestinal Issues: Problems with the gastrointestinal system, such as gastroesophageal reflux or constipation, are common.
  • Growth Anomalies: Affected individuals may experience growth retardation, leading to short stature.
  • Skeletal Abnormalities: Skeletal issues, including scoliosis and joint hypermobility, have been reported.

Genetics[edit]

Menke-Hennekam Syndrome is primarily associated with mutations in the CDH1 gene, which encodes E-cadherin, a protein essential for cell adhesion. These mutations are typically inherited in an autosomal dominant pattern, meaning a single copy of the altered gene in each cell is sufficient to cause the disorder. However, there have been cases with no known family history of the syndrome, suggesting the possibility of de novo mutations.

Diagnosis[edit]

Diagnosis of Menke-Hennekam Syndrome is based on clinical evaluation and the identification of characteristic features. Genetic testing for mutations in the CDH1 gene can confirm the diagnosis. Due to the rarity of the syndrome and the variability of its presentation, diagnosis can be challenging and often requires a multidisciplinary approach.

Management and Treatment[edit]

There is no cure for Menke-Hennekam Syndrome, and treatment is symptomatic and supportive. Management strategies may include:

  • Educational Support: Early intervention and special education programs can help address developmental delays and intellectual disabilities.
  • Medical Management: Gastrointestinal and other systemic issues may require specific medical treatments.
  • Physical Therapy: To manage skeletal abnormalities and improve mobility.
  • Regular Monitoring: Ongoing assessment by a team of healthcare providers is essential to address the evolving needs of the individual.

Prognosis[edit]

The prognosis for individuals with Menke-Hennekam Syndrome varies depending on the severity of symptoms and the effectiveness of management strategies. With appropriate support, many affected individuals can lead fulfilling lives.

See Also[edit]

Stub icon
   This article is a medical stub. You can help WikiMD by expanding it!



Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.